CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy

Kidney International Reports - United States
doi 10.1016/j.ekir.2016.08.019
Full Text
Abstract

Available in full text

Categories
Nephrology
Date
Authors
Publisher

Elsevier BV


Related search